Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy
May 20, 2024 11:35 ET
|
ONWARD Medical NV
Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy
ONWARD® Medical plant Webcast zur Vorstellung des Geschäftsverlaufs im 1. Quartal 2024
May 15, 2024 18:43 ET
|
ONWARD Medical NV
EINDHOVEN, Niederlande, May 16, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnologieunternehmen, das innovative Rückenmarkstimulationstherapien entwickelt, um die...
ONWARD® Medical organise un webinaire pour présenter l’état des lieux de ses activités du premier trimestre 2024
May 15, 2024 18:43 ET
|
ONWARD Medical NV
EINDHOVEN, Pays-Bas, 16 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du...
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update
May 14, 2024 18:21 ET
|
ONWARD Medical NV
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update
Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions
May 02, 2024 21:31 ET
|
ONWARD Medical NV
EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du...
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
May 02, 2024 01:00 ET
|
ONWARD Medical NV
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
ONWARD® Medical annonce ses résultats financiers et opérationnels pour l’exercice 2023 et partage les faits qui ont marqué l’exercice 2024 à ce jour
April 26, 2024 09:17 ET
|
ONWARD Medical NV
Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats...
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
April 25, 2024 01:30 ET
|
ONWARD Medical NV
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
April 11, 2024 01:30 ET
|
ONWARD Medical NV
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
April 09, 2024 01:00 ET
|
ONWARD Medical NV
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00